AzTrials
AzTrials

Wet Age-related Macular DegenerationPhase 3NCT05727397

Efficacy and Safety of RC28-E Versus Aflibercept

A Phase 3 study testing RC28-E and Aflibercept in people with Wet Age-related Macular Degeneration, run by RemeGen Co., Ltd. at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Wet Age-related Macular Degeneration
What is being tested?
RC28-E and Aflibercept
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
432 participants
Where
1 siteChina
Study dates
14 Mar 2023to 29 Dec 2025
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Sign the consent form, willing and able to comply with clinic visits and study-related procedures;
  • 50 years of age or older;
  • Diagnosed with wAMD;
  • Active CNV lesion of any type (ie, predominantly classic, minimally classic, or occult [including polypoidal choroidal vasculopathy and retinal angiomatous proliferation]) that exhibits all of the following characteristics:
  • The CNV or sequela of the CNV affect the foveal;
  • A total lesion size of ≤12 disc areas on FFA;
Show all 10Show fewer
  • Evidence of CNV leakage on FFA;
  • Intra and/or subretinal fluid confirmed on OCT;
  • BCVA of 78-19 letters using the ETDRS protocol;
  • Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good-quality retinal images to confirm diagnosis.

Who cannot join

  • For the study eye:
  • CNV due to causes other than AMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis;
  • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid;
  • Presence at screening of central serous chorioretinopathy;
  • Retinal pigment epithelial tear involving the foveola on day 1;
  • Fibrosis or atrophy involves the foveola;
Show all 40Show fewer
  • Subretinal haemorrhage involves the foveola;
  • Any concurrent intraocular condition (eg, amblyopia, aphakia, retinal detachment, cataract, diabetic retinopathy or maculopathy, or epiretinal membrane with traction) that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study;
  • Current vitreous hemonhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to baseline;
  • Uncontrolled glaucoma;
  • Spherical equivalent of refractive error demonstrating ≥8 diopters of myopia;
  • Previous treatment with anti-VEGF therapy within the 3 months period prior to baseline;
  • Intraocular use of long-acting corticosteroids during the 6 month period prior to baseline; intraocular use of short or medium-acting corticosteroids during the 3 month period prior to baseline; periocular use of corticosteroids during the 1 month period prior to baseline;
  • Use of topical ocular corticosteroids for 60 or more consecutive days within the 3 month period prior to baseline;
  • Macular laser treatment, PDT, TTT or other surgical intervention for AMD within the 3 month period prior to baseline;
  • Any cataract surgery or treatment for complications of cataract surgery with steroids within the 3 month period prior to baseline; YAG laser capsulotomy within 1 month before baseline;
  • Aphakia or pseudophakia with absence of posterior capsule, unless it occurred as a result of YAG posterior capsulotomy;
  • Intraocular or refractive surgery within the 3 month period prior to baseline;
  • Previous penetrating keratoplasty or vitrectomy or panretinal photocoagulation or radiotherapy;
  • For the fellow eye or both eyes:
  • Non-functioning non-study eye;
  • Treatment with anti-VEGF therapy within the 7 day period prior to baseline in the nonstudy eye;
  • Any history of idiopathic or autoimmune-associated uveitis in either eye;
  • Current active ocular inflammation or suspected or active ocular or periocular infection in either eye;
  • General exclusion criteria:
  • Any major illness or major surgical procedure within 1 month before screening;
  • Active cancer within the past 12 months except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of <6 and a stable prostate-specific antigen for >12 months;
  • Requirement for continuous use of any medications and treatments indicated as prohibited therapy;
  • Systemic anti-VEGF therapy within the 3 month period prior to baseline;
  • Use of systemic corticosteroids for 30 or more consecutive days within the 3 months prior to baseline, with the exception of low stable doses of corticosteroids (defined as ≤10 mg/day prednisolone or equivalent dose)；
  • Systemic treatment for suspected or active systemic infection on baseline;
  • COVID-19 infection within the 4 week period prior to screening; Hospitalization required severe COVID-19 infection within the 12 month period prior to screening;
  • HBsAg(+) and HBV DNA>ULN;
  • HCV antibody(+); HIV antibody(+); active syphilitic patients;
  • Uncontrolled blood pressure, defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg;
  • Stroke (cerebral vascular accident) or myocardial infarction within the 6 month period prior to baseline;
  • History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications in the opinion of the investigator;
  • Pregnancy or breastfeeding, or intention to become pregnant during the study;
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of RC28-E or to aflibercept injections, study-related procedure preparations (including fluorescein), dilating drops, or any of the anaesthetic and anti-microbial drops used by the patient during the study;
  • Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins and minerals) within the 3 month period prior to baseline.

Trial locations and contacts

1 site in 1 country.

Binghua Xiao contact

86-010-58076833

xiaosir522@163.com

China1 site, 1 recruiting

  • Beijing Hospital

    Beijing, Beijing Municipality, 100730

    Hong Dai, 13910280398, Dai-hong@x263.net

    Recruiting

Other trials in China

About this study

Official title: A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular Degeneration

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

Being tested
RC28-E, Aflibercept

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RC28-EDrug

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

  • AfliberceptDrug

    Also called Eylea

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

Study groups in NCT05727397
Study groupRoleWhat they receive
RC28-EExperimentalRC28-E 2 mg will be initially injected 3 times at 4 week intervals, then each subject will be injected every 12 weeks unless there is disease activity. If disease activity is identified, the subject will be reassigned to receive injections every 8 weeks thereafter, up to study exit.
Receives: Drug: RC28-E
AfliberceptActive comparatorAflibercept 2 mg will be injected 3 times at 4 week intervals, followed by injections every 8 weeks.
Receives: Drug: Aflibercept

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean change from baseline in BCVA at week 48;

    BCVA=Best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.

    Measured: Baseline, week 48

Secondary outcomes (11)

  1. Average change in BCVA from baseline over the period week 36 through week 48;

    For each subject, this endpoint is defined as the average of the changes from Baseline to Weeks 36, 40, 44 and 48.

    Measured: Baseline, weeks 36, 40, 44 and 48.

  2. Proportion of subjects with q12w injection;

    q12w=every 12 weeks

    Measured: Baseline, week 48

  3. Proportion of subjects with q12w injection at week 48 within the subjects with no q8w injection need at week 16, week 20;

    for subjects randomized to RC28-E group only; q12w=every 12 weeks; q8w=every 8 weeks; A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w injection need.

    Measured: Week 16, 20, 48

  4. Proportion of subjects with gain in BCVA of 15/10/5/0 letters or more from baseline to week 48;

    Proportion of subjects; BCVA=Best-corrected visual acuity;

    Measured: Baseline, week 48

  5. Mean change in CST from baseline to week 16, week 48;

    CST=Central retinal subfield thickness

    Measured: Baseline, week 16, 48

  6. Average change in CST from baseline over the period week 36 through week 48;

    CST=Central retinal subfield thickness

    Measured: Baseline, weeks 36, 40, 44 and 48.

  7. Proportion of subjects with presence of intraretinal fluid/subretinal fluid at week 16, week 48;

    Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid/subretinal fluid is an indicator of underlying disease.

    Measured: Baseline, week 16, 48

  8. Percentage of subjects with disease activity present at week 16;

    A disease activity assessment (DAA) was performed to identify q8w injection need. 95% confidence interval (CI) for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

    Measured: Baseline, week 16

  9. Change in choroidal neovascularization (CNV) lesion size from baseline to week 12, week 48;

    CNV lesion size (the area of new blood vessels in the choroid layer of the retina) was measured using fundus fluorescein angiography (FFA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.

    Measured: Baseline, week 12, 48

  10. Proportion of subjects with q8w treatment need at weeks 16, 20, 28, 32, 40, 44;

    q8w=every 8 weeks; A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. This outcome measure was pre-specified for RC28-E arm only.

    Measured: Weeks 16, 20, 28, 32, 40, 44

  11. Incidence and characteristics of ocular and systemic treatment emergent adverse events.

    safety endpoint

    Measured: Baseline, week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2023
  2. Study start14 Mar 2023
  3. Primary completion29 Nov 2025 (estimated)
  4. Study completion29 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
432 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05727397
Sponsor's protocol ID
28C004
Status last verified
Feb 2023
First submitted
10 Jan 2023
Last updated
31 Aug 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing RC28-E and Aflibercept in people with Wet Age-related Macular Degeneration, run by RemeGen Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 40 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 31 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Binghua Xiao (86-010-58076833, xiaosir522@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean change from baseline in BCVA at week 48; (time frame: Baseline, week 48). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05727397.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in